LOGIN
ID
PW
MemberShip
2025-02-07 05:27
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Policy
Prices for Vyndamax, Ocrevus in negotiations with NHIS
by
Lee, Tak-Sun
Jan 3, 2025 06:27am
Pfizer's cardiomyopathy drug Vyndamax Cap and Roche's multiple sclerosis drug Ocrevus Inj are undergoing drug price negotiations with the National Health Insurance Service (NHIS) in Korea. Therefore, it will be interesting to see if the drugs will be able to finalize negotiations and their reimbursement listing agenda be submitted to the He
Policy
Orphan drug 'Voxzogo' wins nod
by
Lee, Hye-Kyung
Jan 2, 2025 06:11am
The Ministry of Food and Drug Safety (Minister Oh Yu-kyoung, MFDS) announced on December 31 that it has approved 'Voxzogo (vosritid),' an orphan drug used to treat achondroplasia in children over four months whose growth plates are not closed. Achondroplasia is a bone growth-related genetic disease caused by a mutation in the FGFR3, a ge
Policy
Changes made to the drug approval system in the new year
by
Lee, Hye-Kyung
Jan 2, 2025 06:11am
Various changes will be made to the drug approval and management system in the new year of 2025, including the new drug approval innovation plan. On December 31st, the Ministry of Food and Drug Safety (MFDS) announced the changes that will be enforced from January, including ¡ã the implementation of a new drug approval innovation plan ¡ã refo
Policy
ICER threshold for anticancer drugs set same as in 2024
by
Lee, Tak-Sun
Jan 2, 2025 06:10am
The Health Insurance Review and Assessment Service released the results of the incremental cost-effectiveness ratio (ICER) of drugs submitted for pharmacoeconomic evaluation from 2019 to 2023, which has shown a decrease in the maximum ICER threshold set for anticancer drugs. The ICER threshold did not appear to have changed much from the prev
Policy
Once-weekly insulin 'Awiqli' wins nod in KOR
by
Lee, Hye-Kyung
Dec 31, 2024 05:56am
A once-weekly insulin to treat patients with adult diabetes has been approved in South Korea. On December 23, the Ministry of Food and Drug Safety has approved Novo Nordisk's 'Awiqli Pre-Filled Pen 700 Units/mL (insulin icodec, recombinant).' This drug is a once-weekly subcutaneous injection of insulin, providing a more convenient treat
Policy
Approval of the 48hr Nurtec ODT for migraine imminent in KOR
by
Lee, Hye-Kyung
Dec 31, 2024 05:55am
¡®Nurtec (Rimegepant),¡¯ which is used for both the treatment and prevention of migraine, will soon receive marketing authorization in Korea. According to industry sources on the 31st, the Ministry of Food and Drug Safety completed the safety and efficacy review of Pfizer's Nurtec Oral Disintegrating Tablet 75 mg. Pfizer submitted a ma
Policy
29 new drugs with 45 ingredients reimb this year
by
Lee, Tak-Sun
Dec 31, 2024 05:55am
This year, 45 new drugs with 29 ingredients were listed for reimbursement benefits under Korea¡¯s health insurance. Among them, the only homegrown new drug was 'Zastaprazan citrate', a P-CAB-based gastroesophageal reflux disease treatment. As of the 30th, 45 new drugs were listed for reimbursement in Korea¡¯s National health insurance syst
Policy
Yungjin Pharm wins the 1st trial against Ofev
by
Kim, Jin-Gu
Dec 31, 2024 05:44am
Yungjin Pharm has won the usage patent dispute for Ofev (nintedanib), a treatment for idiopathic pulmonary fibrosis (IPF). Based on the victory, Yungjin is one step closer to the early launch of its generic version of Ofev. The pharmaceutical industry suggests this decision is significant beyond Yungjin Pharmaceutical's avoidance of Ofe
Policy
K-CAB, Enteresto, Olumiant, Rinvoq signs PVA agreements
by
Lee, Tak-Sun
Dec 30, 2024 05:57am
The domestic P-CAB-based gastroesophageal reflux disease treatment 'K-CAB Tab (tegoprazan, HK Inno.N) and heart failure treatment 'Entresto Film Coated Tab (sacubitril-valsartan-sodium salt complex) the oral JAK inhibitors Olumiant Tab (baricitinib, Lilly), and Rinvoq ER Tab (Upadacitinib hemihydrate, AbbVie) have agreed on a price-volume ag
Policy
7 pharmas newly win 'Innovative Pharmaceutical
by
Lee, Tak-Sun
Dec 30, 2024 05:57am
Seven pharmaceutical companies, including Dong-A ST, have newly acquired the 'Innovative Pharmaceutical Companies Certification.' Five companies, including Ildong Pharmaceutical, received extensions on their certifications. The Ministry of Health and Welfare (MOHW) announced the result of reviewing the 'Innovative Pharmaceutical Companies Cer
1
2
3
4
5
6
7
8
9
10
>